GE HealthCare and Mayo Clinic Collaborate on Theranostics Research for Personalized Cancer Treatment
GE HealthCare and Mayo Clinic have initiated a collaborative research project known as the Molecular Imaging Biomarker-Based End of Therapy (MI-BET) trial. This study is part of the broader Strategic Radiology Research Alliance established in 2023, aiming to enhance the precision of radioligand therapy (RLT) through imaging and biomarker data.
Radioligand therapy is an innovative theranostics approach combining targeted radiopharmaceutical diagnostics with therapies, allowing for more precise cancer treatment. Currently, many patients receiving RLT are subjected to a fixed number of treatment cycles, regardless of individual response. The MI-BET trial seeks to evaluate whether integrating imaging and biomarker insights could tailor treatments to the particular needs of patients with advanced prostate cancer.
Andrew Danielsen, Mayo Clinic’s chief business development officer, emphasized the importance of integrating novel technologies to advance clinical care. Meanwhile, Geoffrey Johnson, MD, PhD, from the Mayo Clinic Comprehensive Cancer Center, stated that the trial could redefine cancer treatment strategies by offering data that supports tailored interventions and broader patient access. The study highlights the potential to reduce unnecessary treatment and facilitate personalized care.
The MI-BET trial will utilize GE HealthCare's StarGuide SPECT/CT technology and MIM Software's MIM LesionID Pro to monitor tumor response. This integration aims to inform treatment decisions and explore the development of predictive markers to better anticipate patient response. By enabling adaptive treatment decisions, this approach could significantly expand the use of precision cancer care.
Sergio Calvo, global general manager of Theranostics at GE HealthCare, indicated the collaboration's potential to foster a deeper understanding of the therapeutic response. The project supports a larger goal of increasing theranostics accessibility, ensuring that advancements in care benefit a diverse patient population through initiatives like telemedicine and partnerships with community organizations.
Research will be conducted at Mayo Clinic's Rochester campus, leveraging both institutions' expertise in clinical practice and research. Additionally, Mayo Clinic will spearhead research into the benefits of GE HealthCare's StarGuide GX technology, which holds potential for reducing scan times and enhancing tumor assessment precision.